disodium (1S,10R,11S,14S,15S)-5-{[bis(2-chloroethyl)carbamoyl]oxy}-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2(7),3,5-trien-14-yl phosphate
| Title | Journal |
|---|---|
| Ablation of the ATP-binding cassette transporter, Abca2 modifies response to estrogen-based therapies. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20120901 |
| Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer. | International journal of clinical oncology 20120601 |
| Docetaxel-induced fatal interstitial pneumonitis in a patient with castration-resistant prostate cancer. | Korean journal of urology 20120501 |
| Castration-resistant prostate cancer: systemic therapy in 2012. | Clinics (Sao Paulo, Brazil) 20120401 |
| Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy. | Journal of clinical immunology 20120201 |
| Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours. | Endocrine-related cancer 20120201 |
| Surgical castration in hormone-refractory metastatic prostate cancer patients can be an alternative for medical castration. | Advances in urology 20120101 |
| Prostate-specific membrane antigen-based therapeutics. | Advances in urology 20120101 |
| Management of high-risk localized prostate cancer. | Advances in urology 20120101 |
| Synergistic Effect of Geranylgeranyltransferase Inhibitor, GGTI, and Docetaxel on the Growth of Prostate Cancer Cells. | Prostate cancer 20120101 |
| A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. | European journal of cancer (Oxford, England : 1990) 20120101 |
| The Role of FoxC2 Transcription Factor in Tumor Angiogenesis. | Journal of oncology 20120101 |
| Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer. | World journal of surgical oncology 20120101 |
| In vitro and in vivo double-enhanced suicide gene therapy mediated by generation 5 polyamidoamine dendrimers for PC-3 cell line. | World journal of surgical oncology 20120101 |
| Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature. | Cancer investigation 20120101 |
| Clinical Efficacy of TroVax in the Treatment of Progressive Castration-resistant Prostate Cancer. | Clinical Medicine Insights. Oncology 20120101 |
| Caffeic acid phenethyl ester causes p21 induction, Akt signaling reduction, and growth inhibition in PC-3 human prostate cancer cells. | PloS one 20120101 |
| Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience. | BMC urology 20120101 |
| Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer. | PloS one 20120101 |
| Pathobiological implications of the expression of EGFR, pAkt, NF-κB and MIC-1 in prostate cancer stem cells and their progenies. | PloS one 20120101 |
| Clinical Indications of C-Choline PET/CT in Prostate Cancer Patients with Biochemical Relapse. | Theranostics 20120101 |
| Redefining hormone sensitive disease in advanced prostate cancer. | Advances in urology 20120101 |
| Exploring the molecular basis of antifungal synergies using genome-wide approaches. | Frontiers in microbiology 20120101 |
| Immunotherapy of genitourinary malignancies. | Journal of oncology 20120101 |
| Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening. | PloS one 20120101 |
| Castration-resistant prostate cancer: mechanisms, targets, and treatment. | Prostate cancer 20120101 |
| Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. | PloS one 20120101 |
| The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer. | Advances in urology 20120101 |
| Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. | PloS one 20120101 |
| Low-dose chemotherapy with insulin (insulin potentiation therapy) in combination with hormone therapy for treatment of castration-resistant prostate cancer. | ISRN urology 20120101 |
| Toward maximizing immunotherapy in metastatic castration-resistant prostate cancer - rationale for combinatorial approaches using chemotherapy. | Frontiers in oncology 20120101 |
| Emerging targeted therapies for castration-resistant prostate cancer. | Frontiers in endocrinology 20120101 |
| Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy. | Advances in urology 20120101 |
| Impact of docetaxel-based chemotherapy on quality of life of patients with castration-resistant prostate cancer: results from a prospective phase II randomized trial. | BJU international 20111201 |
| The use of estramustine phosphate in the modern management of advanced prostate cancer. | BJU international 20111201 |
| Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials. | Journal of cancer research and clinical oncology 20111201 |
| Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). | PLoS computational biology 20111201 |
| Comparison of ketoconazole and estramustine for treating patients with castration-resistant prostate cancer. | Korean journal of urology 20111101 |
| The epothilones: new therapeutic agents for castration-resistant prostate cancer. | The oncologist 20111001 |
| Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. | Cell death & disease 20110701 |
| Efficacy of alternative antiandrogen therapy for prostate cancer that relapsed after initial maximum androgen blockade. | Korean journal of urology 20110701 |
| Limited expression of cytochrome p450 17α-hydroxylase/17,20-lyase in prostate cancer cell lines. | Korean journal of urology 20110701 |
| [Oral antineoplastic agents for prostate cancer]. | Nihon rinsho. Japanese journal of clinical medicine 20110601 |
| Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032. | Urology 20110501 |
| Role of androgen deprivation treatment in patients with castration-resistant prostate cancer, receiving docetaxel-based chemotherapy. | American journal of clinical oncology 20110401 |
| A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer. | The Prostate 20110401 |
| [Long-term disease stabilization by docetaxel plus estramustine for castration-resistant prostate cancer : report of a case]. | Hinyokika kiyo. Acta urologica Japonica 20110401 |
| Castration-resistant prostate cancer: targeted therapies and individualized treatment. | The oncologist 20110301 |
| [A case of castration-refractory prostate cancer showing marked decrease of serum PSA level after zoledronic acid treatment with estramustine phosphate and prednisolone]. | Gan to kagaku ryoho. Cancer & chemotherapy 20110301 |
| Current treatment strategies for castration-resistant prostate cancer. | Korean journal of urology 20110301 |
| Saudi Oncology Society clinical management guidelines for prostate cancer. | Urology annals 20110301 |
| Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study. | British journal of cancer 20110215 |
| A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol. | British journal of cancer 20110215 |
| A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. | Cancer chemotherapy and pharmacology 20110201 |
| A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. | Cancer 20110201 |
| Spirituality and end-of-life care in disadvantaged men dying of prostate cancer. | World journal of urology 20110201 |
| The role of RANK-ligand inhibition in cancer: the story of denosumab. | The oncologist 20110201 |
| Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs. | Bioorganic & medicinal chemistry letters 20110115 |
| Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial. | Urologic oncology 20110101 |
| Prognostic factors for failure after prostatectomy. | Journal of Cancer 20110101 |
| Saddle pulmonary embolism in a cancer patient with thrombocytopenia: a treatment dilemma. | Cardiology research and practice 20110101 |
| Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. | BMC cancer 20110101 |
| Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. | Drug design, development and therapy 20110101 |
| The validation of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) in pre-operative patients with brain tumor in China. | BMC medical research methodology 20110101 |
| Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. | Journal of hematology & oncology 20110101 |
| Replication stress induces micronuclei comprising of aggregated DNA double-strand breaks. | PloS one 20110101 |
| Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. | BMC cancer 20110101 |
| Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization, and cytotoxicity studies. | Nanoscale research letters 20110101 |
| Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments. | OncoTargets and therapy 20110101 |
| Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population. | Cancer management and research 20110101 |
| Fospropofol: clinical pharmacology. | Journal of anaesthesiology, clinical pharmacology 20110101 |
| Peritoneal dissemination of prostate cancer due to laparoscopic radical prostatectomy: a case report. | Journal of medical case reports 20110101 |
| Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis. | BMC cancer 20110101 |
| Control of prostate cancer associated with withdrawal of a supplement containing folic acid, L-methyltetrahydrofolate and vitamin B12: a case report. | Journal of medical case reports 20110101 |
| Resistance to cancer treatment: the role of somatic genetic events and the challenges for targeted therapies. | Frontiers in pharmacology 20110101 |
| Network based consensus gene signatures for biomarker discovery in breast cancer. | PloS one 20110101 |
| Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T? | Clinical Medicine Insights. Oncology 20110101 |
| Bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel. | Prostate cancer 20110101 |
| An aggressive signet ring cell carcinoma of the prostate in a Japanese man. | Case reports in oncology 20110101 |
| Efficacy and safety of a modular multi-modal exercise program in prostate cancer patients with bone metastases: a randomized controlled trial. | BMC cancer 20110101 |
| The state of research into children with cancer across Europe: new policies for a new decade. | Ecancermedicalscience 20110101 |
| Survival benefit during zoledronic acid and docetaxel-based chemotherapy in metastatic hormone-refractory prostate cancer patients: an institutional report. | Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20110101 |
| Sarcomatoid carcinoma of the prostate: ductal adenocarcinoma and stromal sarcoma-like appearance: a rare association. | Case reports in urology 20110101 |
| Cell death signaling and anticancer therapy. | Frontiers in oncology 20110101 |
| A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer. | Anti-cancer drugs 20101101 |
| Cabazitaxel in prostate cancer: stretching a string. | Lancet (London, England) 20101002 |
| [Two cases of pellagra associated with chemotherapy of docetaxel, estramustine, dexamethasone]. | Hinyokika kiyo. Acta urologica Japonica 20101001 |
| Role of radical prostatectomy for high-risk prostate cancer. | Korean journal of urology 20100901 |
| Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. | BJU international 20100801 |
| A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. | Cancer immunology, immunotherapy : CII 20100701 |
| Safety and efficacy of docetaxel, estramustine phosphate and hydrocortisone in hormone-refractory prostate cancer patients. | International journal of urology : official journal of the Japanese Urological Association 20100701 |
| [Effect of the 5-HT3 receptor antagonist granisetron on estramustine phosphate sodium (Estracyt)-induced emesis in ferrets]. | Hinyokika kiyo. Acta urologica Japonica 20100701 |
| Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer. | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 20100601 |
| Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer. | BJU international 20100501 |
| [Prognostic factors for estrogen therapy of relapsed prostate cancer after maximal androgen blockade (MAB)]. | Nihon Hinyokika Gakkai zasshi. The japanese journal of urology 20100501 |
| Hormonal therapy for prostate cancer: current topics and future perspectives. | International journal of urology : official journal of the Japanese Urological Association 20100401 |
| [Low-dose docetaxel, estramustine and dexamethasone combination chemotherapy for hormone-refractory prostate cancer]. | Hinyokika kiyo. Acta urologica Japonica 20100401 |
| Phase II study of vinorelbine and estramustine in combination with conformational radiotherapy for patients with high-risk prostate cancer. | International journal of radiation oncology, biology, physics 20100315 |
| Neoadjuvant LHRH analog plus estramustine phosphate combined with three-dimensional conformal radiotherapy for intermediate- to high-risk prostate cancer: a randomized study. | International urology and nephrology 20100301 |
| [Chemotherapy with docetaxel in prostate cancer. A case report]. | Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20100301 |
| Metastasis of genitourinary tumors to the head and neck region. | European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 20100201 |
| Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents. | British journal of cancer 20100119 |
| Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone. | Urologic oncology 20100101 |
| Final report on low-dose estramustine phosphate (EMP) monotherapy and very low-dose EMP therapy combined with LH-RH agonist for previously untreated advanced prostate cancer. | Aktuelle Urologie 20100101 |
| [Chemotherapy with low-dose docetaxel and estramustine phosphate in patient with liver dysfunction due to liver metastases of hormone-refractory prostate cancer : a case report]. | Hinyokika kiyo. Acta urologica Japonica 20100101 |
| [Update on the use of estramustin in metastatic prostate cancer]. | Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20100101 |
| Angiogenesis inhibition in prostate cancer: current uses and future promises. | Journal of oncology 20100101 |
| A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899. | Journal of translational medicine 20100101 |
| Metronomic treatment with low-dose trofosfamide leads to a long-term remission in a patient with docetaxel-refractory advanced metastatic prostate cancer. | Case reports in medicine 20100101 |
| A novel synthetic analog of 5, 8-disubstituted quinazolines blocks mitosis and induces apoptosis of tumor cells by inhibiting microtubule polymerization. | PloS one 20100101 |
| Griseofulvin stabilizes microtubule dynamics, activates p53 and inhibits the proliferation of MCF-7 cells synergistically with vinblastine. | BMC cancer 20100101 |
| Quantitative analysis of the effect of tubulin isotype expression on sensitivity of cancer cell lines to a set of novel colchicine derivatives. | Molecular cancer 20100101 |
| Epistatic and functional interactions of catechol-o-methyltransferase (COMT) and AKT1 on neuregulin1-ErbB signaling in cell models. | PloS one 20100101 |
| Modified intention to treat reporting in randomised controlled trials: systematic review. | BMJ (Clinical research ed.) 20100101 |
| Update on options for treatment of metastatic castration-resistant prostate cancer. | OncoTargets and therapy 20100101 |
| A screen for kinetochore-microtubule interaction inhibitors identifies novel antitubulin compounds. | PloS one 20100101 |
| Angiogenesis inhibitors in the treatment of prostate cancer. | Journal of hematology & oncology 20100101 |
| Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients. | BMC cancer 20100101 |
| [11C]choline-PET-guided helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate cancer: local control and toxicity profile after 24 months. | Tumori 20100101 |
| Novel diagnostic biomarkers for prostate cancer. | Journal of Cancer 20100101 |
| Dendritic cell-based immunotherapy for prostate cancer. | Clinical & developmental immunology 20100101 |
| Predicting outcomes of prostate cancer immunotherapy by personalized mathematical models. | PloS one 20100101 |
| Critical appraisal of cabazitaxel in the management of advanced prostate cancer. | Clinical interventions in aging 20100101 |
| Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit. | Cancer management and research 20100101 |
| Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells. | British journal of cancer 20091117 |
| Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. | British journal of cancer 20091020 |
| Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. | British journal of cancer 20091020 |
| Single nucleotide polymorphisms of 17beta-hydroxysteroid dehydrogenase type 7 gene: mechanism of estramustine-related adverse reactions? | International journal of urology : official journal of the Japanese Urological Association 20091001 |
| Increased expression of class III beta-tubulin in castration-resistant human prostate cancer. | British journal of cancer 20090915 |
| Survival after cytotoxic chemotherapy in patients with advanced hormone-resistant prostate cancer: a phase II study. | Oncology reports 20090801 |
| Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer. | International journal of urology : official journal of the Japanese Urological Association 20090801 |
| Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. | British journal of cancer 20090721 |
| A phase I/II trial of fixed-dose docetaxel plus irinotecan and escalating doses of estramustine phosphate for second-line or greater treatment of selected advanced solid tumors. | Anti-cancer drugs 20090701 |
| Skeletal sequelae of cancer and cancer treatment. | Journal of cancer survivorship : research and practice 20090601 |
| Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090520 |
| Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090520 |
| [Toxicity and efficacy of intermittent docetaxel chemotherapy for hormone refractory prostate cancer]. | Aktuelle Urologie 20090501 |
| Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. | Annals of oncology : official journal of the European Society for Medical Oncology 20090401 |
| Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients. | International journal of clinical oncology 20090401 |
| Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02. | International journal of radiation oncology, biology, physics 20090301 |
| Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: Dynamically Modified Outcomes (DYNAMO) analysis of a randomized controlled trial. | Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 20090301 |
| Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20090301 |
| Combining docetaxel with estramustine: back to the future? | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090301 |
| Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells. | British journal of cancer 20090224 |
| Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: interleukin-6 response is a potential early indicator of response to therapy. | Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 20090201 |
| Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience. | Anticancer research 20090201 |
| Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer. | British journal of cancer 20090113 |
| A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate. | Urologic oncology 20090101 |
| Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer. | Oncology 20090101 |
| Advantages of second line estramustine for overall survival of hormone-refractory prostate cancer (HRPC) patients. | Asian Pacific journal of cancer prevention : APJCP 20090101 |
| Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. | Trials 20090101 |
| Small-cell prostate carcinoma: A retrospective analysis of five newly reported cases. | Indian journal of urology : IJU : journal of the Urological Society of India 20090101 |
| Oral chemotherapy in hormone-refractory prostate carcinoma patients unwilling to be admitted to hospital. | Urologia internationalis 20090101 |
| Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081220 |
| Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer. | British journal of cancer 20081209 |
| Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811. | Cancer 20081201 |
| Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer. | BJU international 20081201 |
| Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer. | American journal of clinical oncology 20081201 |
| Novel microtubule-targeting agents - the epothilones. | Biologics : targets & therapy 20081201 |
| Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. | Journal of medicinal chemistry 20081113 |
| Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081110 |
| Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial. | BJU international 20081101 |
| Docetaxel chemotherapy of Korean patients with hormone- refractory prostate cancer:comparative analysis between 1st-line and 2nd-line docetaxel. | Yonsei medical journal 20081031 |
| Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. | Cancer immunology, immunotherapy : CII 20081001 |
| A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004. | Clinical genitourinary cancer 20080901 |
| Kinetic stabilization of microtubule dynamics by estramustine is associated with tubulin acetylation, spindle abnormalities, and mitotic arrest. | Cancer research 20080801 |
| Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group. | Current oncology (Toronto, Ont.) 20080801 |
| The postchemotherapy PSA surge syndrome. | Annals of oncology : official journal of the European Society for Medical Oncology 20080701 |
| Oxaliplatin plus gemcitabine as a salvage schedule for hormone-refractory prostate adenocarcinoma. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20080601 |
| [Estramustine phosphate withdrawal syndrome in relapsed prostate cancer: two case reports]. | Hinyokika kiyo. Acta urologica Japonica 20080601 |
| Re: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. | Journal of the National Cancer Institute 20080507 |
| [Chemotherapy for prostate cancer]. | Presse medicale (Paris, France : 1983) 20080501 |
| Pilot trial of adjuvant paclitaxel plus estramustine in resected high-risk prostate cancer. | Urology 20080501 |
| Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model. | BJU international 20080401 |
| The effect of combined androgen blockade on bone turnover and bone mineral density in men with prostate cancer. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20080301 |
| Editorial comment on: prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience. | European urology 20080201 |
| Editorial comment on: prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience. | European urology 20080201 |
| Prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience. | European urology 20080201 |
| Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC). | Investigational new drugs 20080201 |
| Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. | BJU international 20080201 |
| Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer. | Urology 20080201 |
| Second-line chemotherapy for advanced hormone-refractory prostate cancer. | Clinical advances in hematology & oncology : H&O 20080201 |
| A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer. | British journal of cancer 20080115 |
| Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer. | Cancer chemotherapy and pharmacology 20080101 |
| Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy. | International urology and nephrology 20080101 |
| Long-term control or possible cure? Treatment of stage D2 prostate cancer under chemotherapy using cisplatin and estramustine phosphate followed by maximal androgen blockade. | International urology and nephrology 20080101 |
| Combination chemotherapy with weekly docetaxel and estramustine for hormone refractory prostate cancer in Japanese patients. | International journal of urology : official journal of the Japanese Urological Association 20080101 |
| [Synthetic estrogens: some new pharmacological actions and mechanisms]. | Nihon rinsho. Japanese journal of clinical medicine 20080101 |
| Inhibition of androgen-independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signalling. | Cancer cell international 20080101 |
| Endobronchial metastasis from prostate cancer. | International urology and nephrology 20080101 |
| Comparison of three different chemotherapy regimens containing epirubicin in hormone-refractory prostate cancer patients. | TheScientificWorldJournal 20080101 |
| Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. | Journal of translational medicine 20080101 |
| Novel therapies in genitourinary cancer: an update. | Journal of hematology & oncology 20080101 |
| Evolving perspectives of the role of novel agents in androgen-independent prostate cancer. | Indian journal of urology : IJU : journal of the Urological Society of India 20080101 |
| Phase II study of sequential chemotherapy with docetaxel-estramustine followed by mitoxantrone-prednisone in patients with advanced hormone-refractory prostate cancer. | British journal of cancer 20071217 |
| Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed! | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071210 |
| Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer. | Human gene therapy 20071201 |
| Docetaxel treatment in the elderly patient with hormone refractory prostate cancer. | Clinical interventions in aging 20071201 |
| American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071120 |
| Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. | Journal of the National Cancer Institute 20071107 |
| Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study. | British journal of cancer 20071105 |
| Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. | The Lancet. Oncology 20071101 |
| Estramustine in prostate cancer: new look at an old drug. | The Lancet. Oncology 20071101 |
| [Clinical study on poor PSA response to initial endocrine therapy with MAB or estrogenic drugs for treatment of prostate cancer]. | Nihon Hinyokika Gakkai zasshi. The japanese journal of urology 20071101 |
| [Prostate cancer: future strategies for chemotherapy management]. | Annales d'urologie 20071001 |
| Satraplatin in the treatment of hormone-refractory metastatic prostate cancer. | Therapeutics and clinical risk management 20071001 |
| Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer. | BJU international 20070901 |
| Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior. | Nature clinical practice. Oncology 20070901 |
| Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer. | BJU international 20070801 |
| Epothilones in prostate cancer: review of clinical experience. | Annals of oncology : official journal of the European Society for Medical Oncology 20070701 |
| [Prostate cancer and chemotherapy]. | Bulletin du cancer 20070701 |
| Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20070601 |
| Activity of weekly paclitaxel in advanced hormone-refractory prostate cancer. | American journal of clinical oncology 20070601 |
| [Prostatic carcinoma that arose with hearing loss: a case report]. | Hinyokika kiyo. Acta urologica Japonica 20070601 |
| Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma. | Clinical genitourinary cancer 20070601 |
| A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer. | Clinical genitourinary cancer 20070601 |
| [Mediastinal lymph nodes during the course of a metastatic prostate cancer]. | Actas urologicas espanolas 20070601 |
| Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer. | European urology 20070501 |
| Docetaxel and beyond. | European urology 20070501 |
| Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. | BJU international 20070501 |
| Long-term outcome of a phase II study of weekly docetaxel with a short course of estramustine and enoxaparine in hormone-resistant prostate cancer patients. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20070501 |
| [Optimal treatment for elderly high-risk prostate cancer patients]. | Gan to kagaku ryoho. Cancer & chemotherapy 20070301 |
| Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model. | Cancer chemotherapy and pharmacology 20070201 |
| Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? | Cancer 20070201 |
| Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer. | Hinyokika kiyo. Acta urologica Japonica 20070201 |
| New multidisciplinary prostate bone metastases clinic: first of its kind in Canada. | Current oncology (Toronto, Ont.) 20070201 |
| Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms. | British journal of cancer 20070129 |
| Current indications for chemotherapy in prostate cancer patients. | European urology 20070101 |
| A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. | Health technology assessment (Winchester, England) 20070101 |
| Effect of zoledronic acid on metastatic hormone-refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone. | International journal of urology : official journal of the Japanese Urological Association 20070101 |
| Novel expressed sequences identified in a model of androgen independent prostate cancer. | BMC genomics 20070101 |
| The ABCA2 transporter: intracellular roles in trafficking and metabolism of LDL-derived cholesterol and sterol-related compounds. | Current drug metabolism 20070101 |
| Actual chemotherapeutical possibilities in hormone-refractory prostate cancer (HRPC) patients. | Anticancer research 20070101 |
| Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer. | Cancer journal (Sudbury, Mass.) 20070101 |
| The 5th Conference on Asian Trends in Prostate Cancer Hormone Therapy. | Asian Pacific journal of cancer prevention : APJCP 20070101 |
| Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment. | Oncology research 20070101 |
| The impact of the catechol-O-methyltransferase Val158Met polymorphism on survival in the general population--the HUNT study. | BMC medical genetics 20070101 |
| A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. | BMC cancer 20070101 |
| Distribution of radioiodinated estramustine binding protein antibody in mice with DU-145 prostate cancer xenograft. | Anticancer research 20070101 |
| Metronomic chemotherapy dosing-schedules with estramustine and temozolomide act synergistically with anti-VEGFR-2 antibody to cause inhibition of human umbilical venous endothelial cell growth. | Acta oncologica (Stockholm, Sweden) 20070101 |
| Do general dimensions of quality of life add clinical value to symptom data? | Journal of the National Cancer Institute. Monographs 20070101 |
| The roles of beta-tubulin mutations and isotype expression in acquired drug resistance. | Cancer informatics 20070101 |
| Chemotherapy for hormone-resistant prostate cancer: Where are we today? | Indian journal of urology : IJU : journal of the Urological Society of India 20070101 |
| New therapeutic targets in the treatment of prostate cancer. | Indian journal of urology : IJU : journal of the Urological Society of India 20070101 |
| Treatment algorithm in hormone-resistant prostate cancer: Practical guidelines. | Indian journal of urology : IJU : journal of the Urological Society of India 20070101 |
| The case for early chemotherapy for the treatment of metastatic disease. | The Journal of urology 20061201 |
| Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061201 |
| DNA microarrays in herbal drug research. | Evidence-based complementary and alternative medicine : eCAM 20061201 |
| Phase II study of low-dose docetaxel/estramustine in elderly patients or patients aged 18-74 years with hormone-refractory prostate cancer. | Clinical genitourinary cancer 20061201 |
| Adjuvant and neoadjuvant therapies in high risk localized prostate cancer. | Journal of experimental & clinical cancer research : CR 20061201 |
| The ATP-binding cassette transporter ABCA2 as a mediator of intracellular trafficking. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20061101 |
| Chemotherapy for hormone-refractory prostate cancer. | The Cochrane database of systematic reviews 20061018 |
| Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. | Clinical cancer research : an official journal of the American Association for Cancer Research 20061015 |
| Personalized peptide vaccines: a new therapeutic modality for cancer. | Cancer science 20061001 |
| A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer. | BJU international 20060901 |
| A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer. | Clinical genitourinary cancer 20060901 |
| Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer. | Clinical genitourinary cancer 20060901 |
| A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer. | British journal of cancer 20060821 |
| Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer. | Cancer 20060815 |
| [Treatment strategy for advanced prostate cancer with bone metastases]. | Gan to kagaku ryoho. Cancer & chemotherapy 20060801 |
| A randomized comparative study of endocrine monotherapy and a combination of estramustine phosphate with the endocrine therapy in patients with untreated stage D prostate cancer. | International journal of clinical oncology 20060801 |
| High-grade astrocytoma treated concomitantly with estramustine and radiotherapy. | Journal of neuro-oncology 20060701 |
| Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach. | Expert opinion on investigational drugs 20060701 |
| Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer. | International journal of urology : official journal of the Japanese Urological Association 20060701 |
| Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060620 |
| Protein expression in experimental malignant glioma varies over time and is altered by radiotherapy treatment. | British journal of cancer 20060619 |
| Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate. | Cancer 20060615 |
| Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. | British journal of cancer 20060605 |
| Current chemotherapeutic approaches for androgen-independent prostate cancer. | Current opinion in investigational drugs (London, England : 2000) 20060601 |
| Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer. | Cancer 20060501 |
| Changing perspectives of the role of chemotherapy in advanced prostate cancer. | The Urologic clinics of North America 20060501 |
| Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice. | Cancer biotherapy & radiopharmaceuticals 20060401 |
| Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network. | Clinical genitourinary cancer 20060301 |
| Combination chemotherapy with estramustine phosphate, ifosfamide and cisplatin for hormone-refractory prostate cancer. | Acta medica Okayama 20060201 |
| Doxetaxel: new indication. Prostate cancer: a few more weeks. | Prescrire international 20060201 |
| A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy. | Cancer 20060101 |
| A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. | Journal of translational medicine 20060101 |
| Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. | BMC cancer 20060101 |
| Profiling alternatively spliced mRNA isoforms for prostate cancer classification. | BMC bioinformatics 20060101 |
| Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group. | BMC cancer 20060101 |
| Palliative chemotherapy with trofosfamide in advanced prostate cancer. | Anticancer research 20060101 |
| Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma. | Cancer journal (Sudbury, Mass.) 20060101 |
| Repeated massive tongue swelling due to the combined use of estramustine phosphate and angiotensin-converting enzyme inhibitor. | Journal of investigational allergology & clinical immunology 20060101 |
| Evaluation of lipophilins as determinants of tumor cell response to estramustine. | The Journal of pharmacology and experimental therapeutics 20051201 |
| Therapeutic options in androgen-independent prostate cancer: building on docetaxel. | BJU international 20051201 |
| The Val158Met polymorphism of the catechol-O-methyltransferase gene is associated with the PSA-progression-free survival in prostate cancer patients treated with estramustine phosphate. | European urology 20051101 |
| Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer. | Onkologie 20051101 |
| [Prostate cancer with penile metastasis: a case report]. | Hinyokika kiyo. Acta urologica Japonica 20051101 |
| Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer. | International journal of clinical oncology 20051001 |
| [Prostate cancer: update]. | Bulletin du cancer 20051001 |
| Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. | British journal of cancer 20050919 |
| High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study. | The Journal of urology 20050901 |
| Matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine: tumor-reducing effects on hormone-sensitive prostate cancer in rats. | Anti-cancer drugs 20050901 |
| Prior estrogen therapy as a predictor of response to subsequent estramustine-based chemotherapy in patients with androgen-independent prostate cancer. | Clinical prostate cancer 20050901 |
| Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. | British journal of cancer 20050822 |
| Epothilones and the next generation of phase III trials for prostate cancer. | BJU international 20050801 |
| The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group. | Urology 20050801 |
| In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines. | The Prostate 20050601 |
| Future directions in the treatment of androgen-independent prostate cancer. | Urology 20050601 |
| An interdisciplinary approach to treating prostate cancer. | Urology 20050601 |
| Prediction of genotoxicity of chemical compounds by statistical learning methods. | Chemical research in toxicology 20050601 |
| Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050520 |
| Update in the management of patients with hormone-refractory prostate cancer. | Current opinion in urology 20050501 |
| Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies. | Current oncology reports 20050501 |
| Chemotherapy agents and timing of chemotherapy in prostate cancer management. | Current urology reports 20050501 |
| The current role of chemotherapy in metastatic hormone-refractory prostate cancer. | Urology 20050501 |
| [Hormonoresistant metastatic prostate cancer: analysis of two phase III clinical studies]. | Bulletin du cancer 20050501 |
| Can a rational design for metronomic chemotherapy dosing be devised? | British journal of cancer 20050425 |
| Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients. | The Prostate 20050401 |
| Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate. | European urology 20050401 |
| Synergistic inhibitory effect of high-intensity focused ultrasound combined with chemotherapy on Dunning adenocarcinoma. | BJU international 20050401 |
| Docetaxel for treatment of solid tumours: a systematic review of clinical data. | The Lancet. Oncology 20050401 |
| Which drug combination for hormone-refractory prostate cancer? | Expert opinion on pharmacotherapy 20050401 |
| Recent progress in management of advanced prostate cancer. | Oncology (Williston Park, N.Y.) 20050401 |
| [The place of estramustine in the treatment of prostate cancer]. | Orvosi hetilap 20050320 |
| Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study. | Annals of oncology : official journal of the European Society for Medical Oncology 20050301 |
| Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050301 |
| Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells. | Molecular cancer therapeutics 20050301 |
| Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study. | Urology 20050301 |
| A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20050301 |
| Chemotherapy for androgen-independent prostate cancer. | World journal of urology 20050201 |
| [Chemotherapy for prostate cancer]. | Nihon rinsho. Japanese journal of clinical medicine 20050201 |
| [Treatment of androgen-independent hormone refractory prostate cancer using docetaxel]. | Nihon rinsho. Japanese journal of clinical medicine 20050201 |
| Single-nucleotide polymorphisms in the 17beta-hydroxysteroid dehydrogenase genes might predict the risk of side-effects of estramustine phosphate sodium in prostate cancer patients. | International journal of urology : official journal of the Japanese Urological Association 20050201 |
| New standards in the chemotherapy of metastatic hormone-refractory prostate cancer. | Expert review of anticancer therapy 20050201 |
| Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer. | The Canadian journal of urology 20050201 |
| Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer? | Nature clinical practice. Oncology 20050201 |
| Drug insight: Use of docetaxel in prostate and urothelial cancers. | Nature clinical practice. Urology 20050201 |
| Chemotherapy for advanced prostate cancer. | The New England journal of medicine 20050113 |
| Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment. | Urology 20050101 |
| A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050101 |
| Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer. | Urologic oncology 20050101 |
| Influence of p53 and bcl-2 on chemosensitivity in benign and malignant prostatic cell lines. | Urologic oncology 20050101 |
| Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up. | Urologic oncology 20050101 |
| Administration of estramustine in response to changes in the prostate-specific antigen and Karnofsky index in the treatment of prostate cancer. | In vivo (Athens, Greece) 20050101 |
| Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy. | Urologia internationalis 20050101 |
| Radiation sensitizing effect of estramustine is not dependent on apoptosis. | Anticancer research 20050101 |
| Advances in prostate cancer chemotherapy: a new era begins. | CA: a cancer journal for clinicians 20050101 |
| Docetaxel in hormone-refractory metastatic prostate cancer. | Drugs 20050101 |
| Dose-finding study of weekly docetaxel plus estramustine in patients with hormone-refractory metastatic prostate cancer. | Tumori 20050101 |
| Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience. | Anticancer research 20050101 |
| Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. | The oncologist 20050101 |
| An evaluation of high-doses ketoconazole with hydrocortisone substitution in hormone-refractory prostate cancer. | Acta chirurgica Iugoslavica 20050101 |
| Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma: results of a meta-analysis. | Cancer 20041215 |
| Phase II trial of estramustine and etoposide in androgen-sensitive metastatic prostate carcinoma. | American journal of clinical oncology 20041201 |
| Long-term response to combination therapy with estramustine and somatostatin analogue in a patient with androgen ablation-refractory prostate cancer. | Urology 20041201 |
| Management of patients with hormone refractory prostate cancer. | Clinical oncology (Royal College of Radiologists (Great Britain)) 20041201 |
| Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma. | Cancer 20041101 |
| Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer. | British journal of cancer 20041018 |
| Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. | The New England journal of medicine 20041007 |
| Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20041001 |
| Is there a role for chemotherapy in prostate cancer? | British journal of cancer 20040913 |
| The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model. | British journal of cancer 20040913 |
| Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer. | Clinical prostate cancer 20040901 |
| [A clinical study of estramustine phosphate sodium for the treatment of hot flushes in men with prostate cancer]. | Nihon Hinyokika Gakkai zasshi. The japanese journal of urology 20040901 |
| [Combination therapy with estramustine and docetaxel for hormone refractory prostate cancer]. | Hinyokika kiyo. Acta urologica Japonica 20040801 |
| Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer. | Urology 20040701 |
| Gene expression profiling reveals novel targets of estramustine phosphate in prostate cancer cells. | Cancer letters 20040625 |
| Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer. | The Prostate 20040615 |
| Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation. | British journal of cancer 20040614 |
| Quantification of disseminated tumor cells in the bloodstream of patients with hormone-refractory prostate carcinoma undergoing cytotoxic chemotherapy. | International journal of oncology 20040601 |
| Simultaneous determination of estramustine phosphate and its four metabolites in human plasma by liquid chromatography-ionspray mass spectrometry. | Biomedical chromatography : BMC 20040601 |
| [Chemotherapy of the hormone-refractory prostate cancer]. | Aktuelle Urologie 20040601 |
| Identification of a novel first exon of the human ABCA2 transporter gene encoding a unique N-terminus. | Biochimica et biophysica acta 20040416 |
| Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. | British journal of cancer 20040405 |
| Novel therapeutic strategies for androgen-independent prostate cancer: an update. | Seminars in oncology 20040401 |
| Weekly administration of docetaxel in patients with hormone-refractory prostate cancer: a pilot study on Japanese patients. | Japanese journal of clinical oncology 20040301 |
| Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. | Journal of cellular biochemistry 20040215 |
| Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma. | Cancer 20040215 |
| Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. | International journal of urology : official journal of the Japanese Urological Association 20040201 |
| Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. | The Journal of urology 20040201 |
| [Docetaxel and prostate cancer]. | Bulletin du cancer 20040201 |
| [Potentiation of focal ultrasound treatment of prostate adenocarcinoma by concomitant chemotherapy with estramustine phosphate and paclitaxel]. | Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20040201 |
| Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients. | British journal of cancer 20040126 |
| Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer. | British journal of cancer 20040112 |
| Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study. | Urology 20040101 |
| Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer. | Urologic oncology 20040101 |
| Pilot study of estramustine added to radiosurgery and radiotherapy for treatment of high grade glioma. | Journal of neuro-oncology 20040101 |
| Quality of life and emotional distress in advanced prostate cancer survivors undergoing chemotherapy. | Health and quality of life outcomes 20040101 |
| Single-agent chemotherapy with docetaxel significantly reduces PSA levels in patients with high-grade localized prostate cancers. | Urologia internationalis 20040101 |
| High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. | Anticancer research 20040101 |
| Treatment options in hormone-refractory metastatic prostate carcinoma. | Tumori 20040101 |
| Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. | Urology 20031229 |
| Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), Intergroup/Clinical Trials Support Unit study. | Urology 20031229 |
| Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient. | Urology 20031229 |
| A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. | Cancer 20031215 |
| The evolving role of chemotherapy and other systemic therapies for managing localized prostate cancer. | The Journal of urology 20031201 |
| [Significance of docetaxel in the chemotherapy of hormone-refractory prostate cancer]. | Onkologie 20031201 |
| [Intermittent oral hormonal chemotherapy using estramustine phosphate and etoposide for the treatment of hormone-refractory prostate cancer]. | Hinyokika kiyo. Acta urologica Japonica 20031201 |
| Combination chemotherapy for hormone-refractory prostate carcinoma: progress and pitfalls. | Cancer 20031115 |
| Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial. | Cancer 20031115 |
| Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: a phase II trial of the Fox Chase Network. | Cancer 20031101 |
| Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. | Cancer 20031101 |
| [Chemotherapy of hormone refractory prostate carcinoma]. | Der Urologe. Ausg. A 20031101 |
| Unique induction of p21(WAF1/CIP1)expression by vinorelbine in androgen-independent prostate cancer cells. | British journal of cancer 20031020 |
| Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. | Annals of oncology : official journal of the European Society for Medical Oncology 20031001 |
| What next after hormonotherapy in cancer prostate? | Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 20031001 |
| Prostate cancer and bone metastases: medical treatment. | Clinical orthopaedics and related research 20031001 |
| Intermittent chemotherapy in metastatic androgen-independent prostate cancer. | British journal of cancer 20030915 |
| Weekly paclitaxel plus estramustine combination therapy in hormone-refractory prostate cancer: a pilot study. | International journal of urology : official journal of the Japanese Urological Association 20030901 |
| Enzyme-mediated precipitation of parent drugs from their phosphate prodrugs. | International journal of pharmaceutics 20030811 |
| Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma. | Cancer 20030715 |
| Chemotherapy of prostate cancer: present and future. | Current urology reports 20030601 |
| [Malignant priapism as a sign of a recurrent prostate cancer. Differential diagnosis of induratio penis plastica]. | Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20030601 |
| Current strategies in the management of hormone refractory prostate cancer. | Cancer treatment reviews 20030601 |
| Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030601 |
| The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group. | Urology 20030601 |
| Docetaxel (taxotere) in the treatment of prostate cancer. | Expert review of anticancer therapy 20030601 |
| Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells. | The Journal of biological chemistry 20030516 |
| Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. | The Journal of urology 20030501 |
| Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinoma. | Cancer 20030501 |
| Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer. | Urology 20030401 |
| [Prostatic cancer in the young adult]. | Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20030401 |
| Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030301 |
| Current studies with docetaxel in hormone-refractory prostate cancer: selected presentations from the 27th European Society for Medical Oncology Congress, 2002. | Clinical prostate cancer 20030301 |
| A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma. | Cancer 20030201 |
| Bisphosphonate therapy for hormone refractory prostate cancer with bone metastasis. | The Journal of urology 20030101 |
| A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targeting. | Anti-cancer drugs 20030101 |
| Estimating survival benefit in castrate metastatic prostate cancer: decision making in proceeding to a definitive phase III trial. | Urology 20030101 |
| Role of chemotherapy in hormone-refractory prostate cancer. Old issues, recent advances and new perspectives. | Urologia internationalis 20030101 |
| High-risk localized prostate cancer: primary surgery and adjuvant therapy. | Urologic oncology 20030101 |
| Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints. | Urologic oncology 20030101 |
| Hormone refractory advanced prostate cancer treated with estramustine and paclitaxel combination. | Anticancer research 20030101 |
| Beta class II tubulin predominates in normal and tumor breast tissues. | Breast cancer research : BCR 20030101 |
| Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone-refractory prostate cancer. | Cancer journal (Sudbury, Mass.) 20030101 |
| [Cell therapy and prostate cancer]. | Bulletin du cancer 20030101 |
| Docetaxel for the treatment of hormone-refractory prostate cancer. | Reviews in urology 20030101 |
| E-1899: An Eastern Cooperative Oncology Group Study Comparing Ketoconazole Plus Hydrocortisone with Docetaxel Plus Estramustine for Asymptomatic, Androgen-Independent, Nonmetastatic Prostate Cancer Patients with Rising PSA Levels. | Reviews in urology 20030101 |
| A multi-institutional pilot study of adjuvant docetaxel for patients with prostate cancer at high risk for relapse after radical prostatectomy. | Reviews in urology 20030101 |
| Docetaxel for the treatment of hormone-refractory prostate cancer. | Reviews in urology 20030101 |
| E-1899: An Eastern Cooperative Oncology Group Study Comparing Ketoconazole Plus Hydrocortisone with Docetaxel Plus Estramustine for Asymptomatic, Androgen-Independent, Nonmetastatic Prostate Cancer Patients with Rising PSA Levels. | Reviews in urology 20030101 |
| A multi-institutional pilot study of adjuvant docetaxel for patients with prostate cancer at high risk for relapse after radical prostatectomy. | Reviews in urology 20030101 |
| Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. | The Journal of urology 20021201 |
| Editorial: States and state transitions are all that really matter. | The Journal of urology 20021201 |
| An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer. | Urology 20021201 |
| Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustine. | Urology 20021201 |
| [Chemotherapy for prostate cancers]. | Nihon rinsho. Japanese journal of clinical medicine 20021201 |
| [Therapy for hormone-refractory prostate cancer]. | Nihon rinsho. Japanese journal of clinical medicine 20021201 |
| Pattern of somatic androgen receptor gene mutations in patients with hormone-refractory prostate cancer. | Laboratory investigation; a journal of technical methods and pathology 20021101 |
| [Hormonal chemotherapy for hormone-refractory prostate cancer]. | Hinyokika kiyo. Acta urologica Japonica 20021101 |
| Combined anti-microtubule therapy: a phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20021001 |
| Drug resistance in prostate cancer cell lines is influenced by androgen dependence and p53 status. | Urological research 20021001 |
| Penile metastasis of prostatic adenocarcinoma. | International journal of urology : official journal of the Japanese Urological Association 20021001 |
| Weekly epirubicin in patients with hormone-resistant prostate cancer. | British journal of cancer 20020923 |
| Chemotherapy for prostate cancer. | Urology 20020901 |
| Hypertriglyceridemia and pancreatitis associated with estramustine phosphate. | American journal of clinical oncology 20020801 |
| Editorial: the coming revolution in the treatment of prostate cancer patients. | Seminars in urologic oncology 20020801 |
| Chemotherapy for androgen-independent prostate cancer. | Seminars in urologic oncology 20020801 |
| Ondansetron but not granisetron affect cell volume regulation and potassium ion transport of glioma cells treated with estramustine phosphate. | Journal of cancer research and clinical oncology 20020801 |
| [Second cancer after starting treatment for prostate cancer]. | Gan to kagaku ryoho. Cancer & chemotherapy 20020801 |
| High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. | British journal of cancer 20020605 |
| Acute estramustine-induced hypocalcemia unmasking severe vitamin D deficiency. | The American journal of medicine 20020601 |
| Effects of docetaxel on pain due to metastatic androgen-independent prostate cancer. | Current urology reports 20020601 |
| Docetaxel in the integrated management of prostate cancer. Current applications and future promise. | Oncology (Williston Park, N.Y.) 20020601 |
| The role of chemotherapy in advanced prostate cancer. | The Canadian journal of urology 20020601 |
| Estramustine phosphate combined with orchidectomy as first-line therapy in patients with prostate carcinoma. Effect of age on survival. | Cancer 20020515 |
| Estramustine phosphate enhances the effects of hyperthermia and induces the small heat shock protein HSP27 in the human prostate carcinoma cell line PC-3. | Urological research 20020501 |
| A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone. | Cancer 20020315 |
| Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. | Cancer 20020301 |
| A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20020301 |
| Phase I clinical and pharmacologic trial of intravenous estramustine phosphate. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020215 |
| The flare in alkaline phosphatase activity post-orchidectomy predicts which patient may benefit from early chemotherapy in metastatic prostate cancer. | The Prostate 20020201 |
| Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study. | Cancer 20020201 |
| EMP combination chemotherapy and low-dose monotherapy in advanced prostate cancer. | Expert review of anticancer therapy 20020201 |
| In vitro and in vivo activity of LS 4477 and LS 4559, novel analogues of the tubulin binder estramustine. | European journal of cancer (Oxford, England : 1990) 20020101 |
| Controversies in chemotherapy of prostate cancer. | Frontiers of radiation therapy and oncology 20020101 |
| The antimicrotubule drug estramustine but not irradiation induces apoptosis in malignant glioma involving AKT and caspase pathways. | Journal of neuro-oncology 20020101 |
| Phase I trial of oral estramustine and 3-hr infusional paclitaxel for the treatment of hormone refractory prostate cancer. | Cancer investigation 20020101 |
| Estramustine plus a taxane for advanced prostate cancer: the new standard therapy? | Cancer investigation 20020101 |
| Mechanism of action of antitumor drugs that interact with microtubules and tubulin. | Current medicinal chemistry. Anti-cancer agents 20020101 |
| Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements. | Acta oncologica (Stockholm, Sweden) 20020101 |
| Regulation of Cyp1a1 induction by dioxin as a function of cell cycle phase. | The Journal of pharmacology and experimental therapeutics 20011101 |
| Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells. | British journal of cancer 20011101 |
| [Clinical efficacy of leuprolide acetate and combined treatment with estramustine for advanced prostate cancer]. | Nihon Hinyokika Gakkai zasshi. The japanese journal of urology 20011101 |
| [A male case of primary bilateral breast cancers during estrogen therapy for prostate cancer]. | Nihon Hinyokika Gakkai zasshi. The japanese journal of urology 20011101 |
| Combination therapy in hormone-refractory prostate cancer. | Current oncology reports 20010901 |
| Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells. | British journal of cancer 20010901 |
| Single-agent estramustine phosphate (EMP) is active in advanced breast cancer after failure with anthracyclines and taxanes. | Annals of oncology : official journal of the European Society for Medical Oncology 20010901 |
| Secondary myelodysplastic syndrome after treatment of prostate cancer with oral estramustine. | American journal of hematology 20010801 |
| Treatment of hormone refractory prostate cancer. | Seminars in urologic oncology 20010801 |
| Can chemotherapy alter the course of prostate cancer? | Seminars in urologic oncology 20010801 |
| Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. | Seminars in oncology 20010801 |
| Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer. | Seminars in oncology 20010801 |
| Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer. | Seminars in oncology 20010801 |
| Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report. | Seminars in oncology 20010801 |
| Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer. | Seminars in oncology 20010801 |
| Induction of apoptosis by estramustine phosphate mediated by phosphorylation of bcl-2. | Journal of neuro-oncology 20010801 |
| Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer. | Urology 20010701 |
| Estramustine-related hypocalcemia in patients with prostate carcinoma and osteoblastic metastases. | Urology 20010701 |
| A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma. | Cancer 20010601 |
| Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma: a phase II trial of oral estramustine and oral etoposide. | Cancer 20010601 |
| Paclitaxel and docetaxel in prostate cancer. | Hematology/oncology clinics of North America 20010601 |
| Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010501 |
| Diverging effects of 5-HT3 receptor antagonists ondansetron and granisetron on estramustine-inhibited cellular potassium transport. | Pharmacology & toxicology 20010501 |
| Estramustine potentiates taxane in prostate and refractory breast cancers. | Oncology (Williston Park, N.Y.) 20010501 |
| The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study. | Annals of oncology : official journal of the European Society for Medical Oncology 20010501 |
| Distribution of estramustine-binding protein during postnatal development of rat brain. | Histochemistry and cell biology 20010501 |
| Cloning and characterization of human adenosine 5'-triphosphate-binding cassette, sub-family A, transporter 2 (ABCA2). | Cancer research 20010415 |
| Neoadjuvant estramustine and etoposide followed by concurrent estramustine and definitive radiotherapy for locally advanced prostate cancer: feasibility and preliminary results. | International journal of radiation oncology, biology, physics 20010301 |
| A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407). | The Prostate 20010301 |
| The bleb formation of the extracellular pseudopodia; early evidence of microtubule depolymerization by estramustine phosphate in glioma cell; in vitro study. | Journal of neuro-oncology 20010301 |
| The Collection of Indirect and Nonmedical Direct Costs (COIN) form: a new tool for collecting the invisible costs of androgen independent prostate carcinoma. | Cancer 20010215 |
| Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. | Lancet (London, England) 20010203 |
| Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. | Urology 20010201 |
| Current status of cytotoxic chemotherapy in hormone refractory prostate cancer. | European urology 20010201 |
| Necessity of re-evaluation of estramustine phosphate sodium (EMP) as a treatment option for first-line monotherapy in advanced prostate cancer. | International journal of urology : official journal of the Japanese Urological Association 20010201 |
| Docetaxel in prostate cancer. | Anti-cancer drugs 20010201 |
| Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010101 |
| Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer. | Oncology 20010101 |
| A reexamination of PSC 833 (Valspodar) as a cytotoxic agent and in combination with anticancer agents. | Cancer chemotherapy and pharmacology 20010101 |
| Progressing prostate carcinoma. | The oncologist 20010101 |
| Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients. | Anticancer research 20010101 |
| Treatment options in hormone-refractory prostate cancer: current and future approaches. | Drugs 20010101 |
| The treatment challenge of hormone-refractory prostate cancer. | Cancer control : journal of the Moffitt Cancer Center 20010101 |
| [Chemotherapy of prostate cancer: potential role of docetaxel]. | Tumori 20010101 |
| Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor. | Biochemical pharmacology 19980501 |
| Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer. | American journal of clinical oncology 19970801 |
| Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study. | British journal of cancer 19970101 |
| A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer. | The Journal of urology 19860901 |
| Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. | The Journal of urology 19860201 |
| Cardiovascular complications of estrogen therapy for nondisseminated prostatic carcinoma. A preliminary report from a randomized multicenter study. | Scandinavian journal of urology and nephrology 19860101 |
| Cooperative clinical trials of the National Prostatic Cancer Project: Protocol 900. | The Prostate 19840101 |
| Stricture of the anterior urethra following estrogen therapy in patients with prostatic cancer. | Urologia internationalis 19830101 |
| Cardiovascular complications in the treatment of prostatic carcinoma. | British journal of urology 19811201 |
| Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt) or conventional estrogen. A follow-up of 212 randomized patients. | Scandinavian journal of urology and nephrology. Supplementum 19800101 |